Jasper Therapeutics has 914% upside potential, with exclusive licensing agreements and strong analyst ratings.

From Yahoo Finance: 2025-05-21 11:23:00

Jasper Therapeutics, Inc. (JSPR) is a biotech company with a 914% upside potential over the next 12 months, focusing on developing therapeutics for mast and hematopoietic stem cell-driven diseases like chronic urticaria and asthma. They have exclusive licensing agreements with Amgen and Stanford University for their lead product candidate, briquilimab.

In the first quarter of 2025, Jasper Therapeutics reported a net loss of $21.2 million due to increased operating expenses in research and development. Cash balance is at $49.2 million, with operating expenses at $15.1 million. Analysts have a ‘Strong Buy’ rating on JSPR, with a price target estimated at $49.89, indicating 914% upside potential.

On May 15, 2025, Oppenheimer analyst Jay Olson reaffirmed an ‘Outperform’ rating for Jasper Therapeutics, with a revised price target. JSPR ranks 1st on the list of 13 Best Multibagger Stocks to Invest in Now, but some AI stocks are seen as having greater potential for higher returns with limited downside risk.



Read more at Yahoo Finance: Analysts See 914% Upside Potential